SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?

扫码查看

原文链接

作者：

Dimitrios Patoulias、Theodoros Michailidis

展开 >

作者单位：

Second Propedeutic Department of Internal Medicine,Aristotle University of Thessaloniki,General Hospital"Hippokration,"Thessaloniki,Greece

Second Department of Internal Medicine,Aristotle University of Thessaloniki,General Hospital"Hip-pokration,"Thessaloniki,Greece

出版年：

2022

DOI：

临床与转化肝病杂志(英文版)

ISSN：

年,卷(期)：2022.10(4)